Belvedere Trading’s Pliant Therapeutics PLRX Stock Holding History

Belvedere Trading’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-6,490	Closed	-$125K	–	367
2022 Q2	$125K	Buy	+6,490	New	+$41.6K	﹤0.01%	230

Other funds holding PLRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Belvedere Trading's PLRX Position: Q3 2022 in Review

Belvedere Trading sold out of Pliant Therapeutics (PLRX) in Q3 2022, closing a stake of 6,490 shares — an estimated $125K sold.

Belvedere Trading first reported a position in PLRX in Q2 2022 and held it in 1 quarter. The position peaked at $125K in Q2 2022. 110 funds tracked by Wall St. Rank hold PLRX as of Q3 2022.

Belvedere Trading reported no remaining Pliant Therapeutics position as of Q3 2022 after selling out during the quarter.
Belvedere Trading sold 6,490 Pliant Therapeutics shares in Q3 2022, an estimated $125K.
Belvedere Trading first reported a position in Pliant Therapeutics in Q2 2022 and held it in 1 quarter.
Belvedere Trading's Pliant Therapeutics position peaked at $125K in Q2 2022.
110 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2022.

Based on Belvedere Trading's 13F filing for Q3 2022, filed 26 Oct 2022.